Patient-Centered Outcomes: Focusing on the Patient

Program

Preliminary Program - Saturday, May 18, 2013
8:00AM – 5:00PM
PRE-MEETING SHORT COURSES
5:15PM – 6:15PM
EDUCATIONAL SYMPOSIUM (sponsored by ICON)
OLD WINE IN NEW BOTTLES: DO COMPARATIVE EFFECTIVENESS AND PATIENT-CENTERED OUTCOMES RESEARCH REPRESENT A NEW PARADIGM IN HEALTH RESEARCH?
Preliminary Program - Sunday, May 19, 2013
8:00AM-5:00PM
PRE-MEETING SHORT COURSES
3:15PM-5:15PM
ISPOR IN ACTION (Grand Ballroom A (5th Floor), Sheraton New Orleans, New Orleans, LA, USA

ISPOR group leaders report on recent activities, all attendees welcome.

3:15PM-3:20PM WELCOME & OVERVIEW

Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR President
Marilyn Dix Smith, RPh, PhD, ISPOR Executive Director

3:20PM-3:40PM ISPOR Consortium/NETWORKS

Asia Consortium: Surachat Ngorsuraches, PhD, RPh
Latin America Consortium: Gabriela Tannus Araújo, MBA, MSc
Central & Eastern European Network: Vitaly Omelianovskiy, MD, PhD

3:40PM-4:10PM ISPOR Councils

Student Council: Emily Reese, MPH
Student Chapter Faculty Advisory Council: Karen Rascati, RPh, PhD
Institutional Council: John O’Donnell, PhD, MA
Health Science Policy Council: Lou Garrison, PhD
Health Technology Assessment Council: Finn Borlum Kristensen, MD, PhD

4:10PM-4:45PM ISPOR Health Science Task Force Discussions

Budget Impact Analysis Good Practices II Task Force: Sean Sullivan, PhD
Conjoint Analysis-Statistical Analysis, Results & Conclusions Good Research Practices Task Force: Brett Hauber, PhD
Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force: Don Husereau, BSc Pharm, MSc
Clinician-Reported Outcomes (ClinROs) Good Measurement Practices Task Force: John Powers, MD, FACP, FIDSA
Mixed Modes to Collect Patient-Reported Outcomes (PRO) Data in Clinical Trials Task Force: Sonya Eremenco, MA
Outcomes Research Methodology Matrix Task Force: Ansgar Hebborn, PhD

4:45PM-5:10PM ISPOR Special Interest Group Discussions

Health Outcomes Metrics Special Interest Group: David Vanness, PhD
Health Technology Assessment Special Interest Group: Annie Chicoye, PhD
Medication Adherence and Persistence (MAP) Special Interest Group: John Zeber, PhD, MHA
Oncology Special Interest Group: Kathy Schulman, MA
Rare Disease Special Interest Group: Nadia Naaman

5:10PM-5:15PM Open Discussion & Closing Remarks (All Attendees, Deborah Marshall, PhD, MHSA)
5:15PM-6:15PM
EDUCATIONAL SYMPOSIUM (Sponsored by the National Pharmaceutical Council)
ASSESSING THE EVIDENCE FOR BETTER PATIENT CARE: SYNTHESIZING THE BODY OF EVIDENCE – A TOOL FOR FORMULARY DECISION MAKING
6:30PM-7:30PM
EDUCATIONAL SYMPOSIUM (Sponsored by Optum)
ANALYZE THIS: GETTING THE RIGHT DATA FOR RESEARCH AND EVIDENCE GENERATION
6:30PM-8:30PM
ISPOR STUDENT RESEARCH COMPETITION
The Student Research Competition, now in its 8th year, is a quiz competition featuring teams from ISPOR Student Chapters.  Questions are from the ISPOR Book of Terms and ISPOR Good Practices for Outcomes Research, 17 teams will participate this year.   The top three winning teams receive cash prize for their ISPOR Student Chapter, sponsored by ISPOR.  
8:30PM-9:30PM
ISPOR STUDENT & FACULTY ADVISOR COUNCIL ICEBREAKER RECEPTION
Program - Monday, May 20, 2013
7:15AM-8:15AM
EDUCATIONAL SYMPOSIUM (Sponsored by LASER ANALYTICA)
MULTI-CRITERIA DECISION MAKING IN AMERICA: SEA CHANGE OR NATURAL EVOLUTION?
8:30AM-2:15PM
8:30AM-10:30AM
WELCOME & FIRST PLENARY SESSION
WELCOME & PRESIDENTIAL ADDRESS
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

MEETING PROGRAM OVERVIEW

Laurie B. Burke MPH, RPh
Program Committee Co-Chair and Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

Donald L. Patrick, PhD, MSPH
Program Committee Co-Chair, Professor, Department of Health Services and Director, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

ISPOR 2013 AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
Presented by: Sean D. Sullivan, PhD, RPh, Chair, ISPOR Avedis Donabedian Lifetime Achievement Award in Health Outcomes Committee & Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA
Josephine A. Mauskopf, PhD, MHAAWARDEE: Josephine A. Mauskopf, PhD, MHA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
 

The new buzz words are ‘patient-centered’ and ‘patient-focused’.  Why is the focus on the patient?  Why wasn’t the focus on the patient before now?  What is being done differently to truly focus on the patient in health care delivery and health technology (drug) development?  During this session, steps for assuring the patient is the focus of effectiveness research and drug development will be presented from the perspective of the FDA, PCORI (Patient-Centered Outcomes Research Institute) and a patient.  The new FDA patient-focused drug development program will be discussed as well as the PCORI effectiveness research agenda.  In addition, the definition of patient-centered outcomes, and its use by these organizations will be explored.  An ISPOR member (a patient) will describe her perspective on patient-centered outcomes and the U.S. health care system.

9:00 - 9:10AM Moderator:  Laurie B. Burke, MPH, RPh, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
9:10 - 9:25AM What Does "Patient-Centered Outcomes" Mean?
Speaker: Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services, University of Washington, Seattle, WA, USA
9:25 - 9:40AM FDA's Programs to Increase Patient Focus in the Drug Development Process
Speaker:  Theresa Mullin, PhD, Director, Office of Planning and Informatics, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
9:40 - 9:55AM PCORI's Programs to Assure the Patient is the Center of Effectiveness Research
Speaker:  Joe V. Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
9:55 - 10:10AM  

The Patient – What Outcomes are Important to the Patient in Health Care?
Speaker: The Patient

10:10 - 10:30AM  

DISCUSSION

10:30AM-11:00AM
11:00AM-12:00PM
ISSUE PANELS – SESSION I
11:00AM-12:00PM
Clinical Outcomes Research Issues
IP1: ARE ADMINISTRATIVE CLAIMS DATA BECOMING OBSOLETE?
Moderator: Marc Berger, MD, Vice President, Real World Data & Analytics, Pfizer, Inc., New York, NY, USA
Panelists:

David Thompson, PhD, Senior Vice President, Real World & Late Phase Research, Quintiles Outcome, Cambridge, MA, USA; William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

11:00AM-12:00PM
ECONOMIC OUTCOMES RESEARCH ISSUES
IP2: CAN A LIFE-EXTENDING DRUG BE COST-INEFFECTIVE EVEN IF OFFERED FOR FREE? THE CURIOUS ECONOMICS OF COSTS IN ADDED YEARS OF LIFE
Moderator: Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Panelists: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Mohan Bala, BS, Head, Oncology Market Access, Sanofi, Cambridge, MA, USA; Joshua T. Cohen, PhD, Associate Professor, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
11:00AM-12:00PM
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP3: HOW DO WE BALANCE PATIENT VALUE AND PAYER COST IN ONCOLOGY?
Moderator: Dana Goldman, PhD, Norman Topping Chair in Medicine and Public Policy, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA
Panelists: Peter Bach, MD, MAPP, Director & Attending Physician, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Darius Lakdawalla, PhD, Professor & Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA; Joseph Leveque, MD, Vice President, US Medical - Oncology, Bristol-Myers Squibb, Plainsboro Township, NJ, USA
11:00AM-12:00PM
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP4: HOW CAN COMPARATIVE EFFECTIVENESS RESEARCH PLAY A MEANINGFUL ROLE IN ADDRESSING DISPARITIES IN HEALTH CARE? A MULTI-NATIONAL DIALOGUE
Moderator: Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA
Panelists: Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Antony Morgan, MSc, PhD, FFPH, Associate Director, National Institute for Health and Clinical Excellence (NICE), London, UK; Bernd H. Brüggenjürgen, MD, MPH, Head, Institute for Health Economics, Steinbeis-University Berlin GmbH, and Vice Chairman, German Association for Health Sciences and Public (DVGPH), Berlin, Germany
11:00AM-12:00PM
IP5: RULES OF ENGAGEMENT IN DRUG DEVELOPMENT: ACTIVATING THE PATIENT VOICE (ISPOR Invited Issue Panel)
Moderator: Eleanor M. Perfetto, PhD, MS, Senior Director, Reimbursement & Regulatory Affairs, Federal Government Relations, Pfizer, Inc., Washington, DC, USA
Panelists: Cynthia Bens, BA, Vice President of Public Policy, Alliance for Aging Research, Washington, DC, USA; Myriam Marquez, BA, JD, National Early-Stage Advisor, Alzheimer’s Association, Seattle, WA, USA
Eleanor M. Perfetto, PhD, MS Cynthia Bens, BA Myriam Marquez, BA, JD
E. M. Perfetto C. Bens M. Marquez
12:00PM-2:15PM
12:15PM-1:15PM
EDUCATIONAL SYMPOSIUM (Sponsored by IMS Health)
THE POWER OF REAL-WORLD EVIDENCE (RWE): FILLING THE GAP BETWEEN BASIC RESEARCH AND DECISION MAKING
12:15PM-1:15PM
ISPOR STUDENT RESEARCH SHOWCASE
 

This session will feature 4 outcomes research studies, conducted by ISPOR student members and presented at the ISPOR 18th Annual International Meeting, which will have a high impact on patient centered outcomes. A brief summary of the research study and conclusions will be presented and then the impact of the study on patient centered outcomes will be discussed.

Moderators: Eberechukwu Onukwugha, PhD, MS, Assistant Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Zeba M. Khan, PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA

Speakers: Tarun Bhagnani, MS, Graduate Student, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA; Tamar Bregje Wissing, Master Student, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands; Abdulkhaliq J. Alsalman, MS, PhD candidate, Department of Pharmacotherapy and Outcomes Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA; Carrie Savage Bennette MPH, PhD Student, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
1:15PM-2:15PM
2:15PM-3:15PM
RESEARCH PODIUM PRESENTATIONS – SESSION I
 

CANCER OUTCOMES RESEARCH

2:15PM-2:30PM
CA1 BREAST CANCER PATIENTS RECEIVING GUIDELINE-CONCORDANT ADJUVANT THERAPY REGIMENS HAVE BETTER ALL-CAUSE AND DISEASE-SPECIFIC SURVIVAL: NEW FINDINGS FROM RURAL GEORGIA
  Lipscomb J1, Guy GP2, Gillespie T3, Goodman M1, Richardson LC2, Ward KC1
1Emory University, Rollins School of Public Health, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA, 3Emory University School of Medicine, Atlanta, GA, USA
2:30PM-2:45PM
CA2 EVALUATION OF SURVIVAL OUTCOMES IN SELECT FIRST-LINE TREATMENT REGIMENS FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
  Bhor M1, Winfree KB2, Sail K1, Zagar A2, Pohl G2, Dhanda R1
1McKesson Specialty Health, The Woodlands, TX, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
2:45PM-3:00PM
CA3 TREATMENT PATTERNS AFTER CASTRATION RESISTANT PROSTATE CANCER (CRPC) DIAGNOSIS: A EUROPEAN PHYSICIAN SURVEY
  Pokras SM1, Zyczynski TM2, Lees M3, Jiao X1, Blanchette C1, Powers J4
1IMS Health, Alexandria, VA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4University of Colorado, Denver, Aurora, CO, USA
3:00PM-3:15PM
CA4 THE USE OF TRANSARTERIAL CHEMOEMBOLIZATION FOR TREATING HEPATOCELLULAR CARCINOMA IN THE SEER-MEDICARE POPULATION
  Breunig IM1, Shaya FT1, Hanna NN2, Chirikov VV1, Seal B3, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA
 

CONCEPTUAL PAPERS

2:15PM-2:30PM
CP1 ADJUSTING FOR INFLATION IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES: ARE WE DOING IT WRONG?
  Paulden M
University of Toronto, Toronto, ON, Canada
2:30PM-2:45PM
CP2 THE NOTION OF REPRESENTATIVE LANGUAGES IN THE CONTEXT OF TRANSLATABILITY ASSESSMENT
  Basse SJ, Martin ML, McCarrier KP
Health Research Associates, Inc., Seattle, WA, USA
2:45PM-3:00PM
CP3 PIECEWISE MODELING OF TIME-TO-EVENT DATA WITH FLEXIBLE PARAMETERIZATION OF COVARIATES AND EFFECTS
  Ishak KJ
United BioSource Corporation, Dorval, QC, Canada
3:00PM-3:15PM
CP4 MEASURING HEALTH OUTCOMES IN THE ABSENCE OF RIGOUR: WILFUL IGNORANCE OR DELIBERATE MALPRACTICE?
  Kind P
University of Leeds, Leeds, UK
 

HEALTH CARE STUDIES – EXPENDITURE OR REIMBURSEMENT STUDIES

2:15PM-2:30PM
HC1 ORPHAN DISEASE DRUG COSTS IN THE UNITED STATES: ASSESSMENT OF LAUNCH PRICING TRENDS IN NON-CANCER ORPHAN DISEASES AND THE FUTURE IMPLICATIONS ON HEALTH SYSTEM ACCESS
  Davis EA1, Schwartz EL2
1Metabolic Markets LLC, San Clemente, CA, USA, 2PriceSpective LLC, San Diego, CA, USA
2:30PM-2:45PM
HC2 HEALTH CARE EXPENDITURES AND DEPRESSION AMONG ADULTS WITH CANCER
  Pan X1, Sambamoorthi U2
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA
2:45PM-3:00PM
HC3 DISCREPANCIES BETWEEN FDA APPROVAL AND CMS COVERAGE FOR DRUGS AND DEVICES
  Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
3:00PM-3:15PM
HC4 HOSPITALIZATION COSTS AND OUTCOMES AMONG ELDERLY CANCER PATIENTS IN THE UNITED STATES
  Khanna R1, Jariwala K2, Bentley JP1, Patel A3
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA, 3Medical Marketing Economics, LLC, Oxford, MS, USA
 

HEALTH TECHNOLOGY ASSESSMENT STUDIES

2:15PM-2:30PM
HT1 INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES
  Nicod E, Kanavos P
London School of Economics and Political Science, London, UK
2:30PM-2:45PM
HT2 AGENCY AGREEMENT IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS
  Jaksa A, Demb J, Ho YS, Daniel K
Context Matters, Inc., New York, NY, USA
2:45PM-3:00PM
HT3 ISSUES IN THE SELECTION OF COMPARATORS FOR REGULATORY AND HTA SUBMISSIONS
  DeLozier AM1, Murray JF1, Klopchin MN1, Johnston JA1, Grainger D2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company USA /Australia, West Ryde, Australia
3:00PM-3:15PM
HT4 HEALTH TECHNOLOGY ASSESSMENT LANDSCAPE OF BIOSIMILARS – APPROACHES TO EVALUATIONS AND RESULTS
  Andreykiv M1, Dahal D2
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Hawthorne, NY, USA
 

RESEARCH ON METHODS – PATIENT-REPORTED OUTCOMES STUDIES

2:15PM-2:30PM
PO1 APPLICATION OF ITEM RESPONSE THEORY IN VALIDATING THE MORISKY MEDICATION ADHERENCE SCALE IN PATIENTS WITH HYPERTENSION
  Gupta S1, Goren A2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA
2:30PM-2:45PM
PO2 PSYCHOMETRIC PERFORMANCE OF THE NEI VFQ-25: RASCH ANALYSIS OF THE NEI VFQ-25 AS A MEASURE OF PATIENT-REPORTED VISUAL FUNCTION ACROSS FOUR RETINAL DISEASES
  Petrillo J1, Ferreira A2, Cano S3, Bressler NM4, Lamoureux E5
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharma AG, Basel, Switzerland, 3ScaleReport, Stotfold, UK, 4John Hopkins University School of Medicine, Baltimore, MD, USA, 5University of Melbourne, Melbourne, Australia
2:45PM-3:00PM
PO3 THE PAIN ASSESSMENT FOR LOWER BACK IMPACTS (PAL-I): QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR THE ASSESSMENT OF IMPACTS OF LOW BACK PAIN
 

Ramasamy A1, Blum SI1, McCarrier KP2, Quintanar-Solares M2, Bushnell DM2, Liedgens H3, Martin ML2, Argoff CE4, Patrick DL5, Wallace MS6, Freynhagen R7
1Forest Research Institute, Jersey City, NJ, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Grünenthal GmbH, Aachen, Germany, 4Albany Medical College, Albany, NY, USA, 5University of Washington, Seattle, WA, USA, 6University of California, San Diego, La Jolla, CA, USA, 7Benedictus Krankenhaus Tutzing, Tutzing, Germany

3:00PM-3:15PM
PO4 TRANSLATABILITY ASSESSMENT OF THE YOUTH QUALITY-OF-LIFE INSTRUMENT–WEIGHT MODULE (YQOL-W)
  Conway K1, Patrick DL2, Acquadro C1, Fuller DS3 1MAPI Research Trust, Lyon, France, 2University of Washington, Seattle, WA, USA, 3MAPI Institute, Philadelphia, PA, USA
3:15PM-3:45PM
3:45PM-7:45PM
3:45PM-4:45PM
RESEARCH PODIUM PRESENTATIONS – SESSION II
 

COMPARATIVE EFFECTIVENESS RESEARCH STUDIES

3:45PM-4:00PM CE1 DOES COMPARATIVE EFFECTIVENESS RESEARCH INCREASE ECONOMIC EFFICIENCY?
  Samnaliev M
Children's Hospital Boston, Boston, MA, USA
4:00PM-4:15PM CE2 RECONCILING VARIATIONS IN PROPENSITY SCORE MATCHING (PSM) ALGORITHMS IN OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH (OCER)
  Borah BJ, Heien HC
Mayo Clinic, Rochester, MN, USA
4:15PM-4:30PM CE3 ADVANTAGES OF BAYESIAN ADAPTIVE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER): “RE-ADAPT”ING ALLHAT
  Broglio K1, Ishak J2, Mullins CD3, Connor J1, Luce BR4, Davis B5
1Berry Consultants, Austin, TX, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA, 5The University of Texas School of Public Health, Houston, TX, USA
4:30PM-4:45PM CE4 COMPARATIVE EFFECTIVENESS OF BIOLOGICS FOR THE INDUCTION OF CLINICAL RESPONSE AND REMISSION IN MODERATE TO SEVERE CROHN'S DISEASE: A NETWORK META-ANALYIS (NMA)
  Tongbram V1, Szydlowski V2, Linnehan J2
1Oxford Outcomes, Morristown, NJ, USA, 2Oxford Outcomes, Bethesda, MD, USA
 

INFECTIOUS DISEASE OUTCOMES RESEARCH STUDIES

3:45PM-4:00PM IN1 INTERVIEWS WITH PATIENTS WITH CHRONIC HEPATITIS C (CHC) VIRUS INFECTION DOCUMENT UNMET NEEDS, CONTENT VALIDITY, AND COMPREHENSION OF PROS FOR CLINICAL TRIALS
 

Blackburn S1, McCool R1, Panter C1, Young V1, Peterson S2, Mitchell L2, Machouf N3, Scott J4, Humphrey L1
1Adelphi Values, Manchester, UK, 2Janssen Cilag, Canada, Toronto, ON, Canada, 3L’Actuel Clinic, Montreal, QC, Canada, 4Janssen Global Services, High Wycombe, UK

4:00PM-4:15PM IN2 CLINICAL CHARACTERISTICS AND TREATMENT DURATION AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION INITIATING DIRECT-ACTING ANTIVIRAL THERAPY IN A LARGE COMMERCIAL INSURANCE DATABASE IN THE UNITED STATES
  Bonafede MM1, Suthoff ED2, Eynullayeva E1
1Truven Health Analytics, Cambridge, MA, USA, 2Vertex Pharmaceuticals, Inc., Cambridge, MA, USA
4:15PM-4:30PM IN3 THE BURDEN OF HCV TO INSURERS IN THE UNITED STATES: TRENDS IN HEALTH CARE RESOURCE UTILIZATION 2002-2012
  Simpson KN1, Simpson AN1, Kirbach SE2, Gooch K2
1Medical University of South Carolina, Charleston, SC, USA, 2Abbott Laboratories, Abbott Park, IL, USA
4:30PM-4:45PM IN4 DIRECT AND INDIRECT COST BURDEN OF CHRONIC HEPATITIS C INFECTION IN PRIVATELY-INSURED PATIENTS, STRATIFIED BY LIVER DISEASE SEVERITY
  Tandon N1, Reddy KR2, Lefebvre P3, Parisé H3, Laliberté F3, Pilon D3, Duh MS4, Prabhakar A5, Cho M5, Balart LA6, Fastenau J1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Hospital of the University of Pennsylvania, Philadelphia, PA, USA, 3Groupe d’analyse, Ltée, Montréal, QC, Canada, 4Analysis Group, Inc., Boston, MA, USA, 5Janssen Services, LLC, Titusville, NJ, USA, 6Tulane University Health Sciences Center, New Orleans, LA, USA
 

MEDICATION ADHERENCE STUDIES

3:45PM-4:00PM MA1 IMPACT OF A VALUE-BASED COPAYMENT WAIVER BENEFIT ON MEDICATION ADHERENCE AND SPENDING
  Gibson TB1, Maclean R2, Carls G1, Moore BJ1, Ehrlich ED1, Baigel C3
1Truven Health Analytics, Ann Arbor, MI, USA, 2Bristol-Myers Squibb Company, New York, NY, USA, 3Bristol-Myers Squibb, New York, NY, USA
4:00PM-4:15PM MA2 BEYOND AVERAGE ADHERENCE: TEMPORAL PATTERNS OF MEDICATION ADHERENCE PREDICT HOSPITALIZATION RISK MORE ACCURATELY THAN THE MEDICATION POSSESSION RATIO
  Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ
Analysis Group, Inc., Boston, MA, USA
4:15PM-4:30PM MA3 REVISION AND VALIDATION OF THE MEDICATION ADHERENCE REASONS SCALE (MAR –SCALE)
  Unni EJ1, Farris K2, Olson J3
1Roseman University of Health Sciences College of Pharmacy, South Jordan, UT, USA, 2The University of Michigan, Ann Arbor, MI, USA, 3Intermountain Medical Center, Murray, UT, USA
4:30PM-4:45PM MA4 USING LATENT CLASS PROBABILITY ESTIMATION AND RESIDUAL INCLUSION TO ADDRESS CONFOUNDING IN MEDICATION ADHERENCE MODELING
  Slejko JF1, Garrison L2, Willke RJ3
1University of Washington, Seattle, WA, USA, 2University of Washington School of Pharmacy, Seattle, WA, USA, 3Pfizer Primary Care, New York, NY, USA
 

RESEARCH ON METHODS – MODELING STUDIES

3:45PM-4:00PM MO1 MODELING FUTURE PREVALENCE OF NEUROLOGICAL CONDITIONS AND DEMAND FOR PHARMACEUTICALS IN THE UNITED STATES
  Gallo P, Dall T, Storm M, Chakrabarti R
IHS, Washington, DC, USA
4:00PM-4:15PM MO2 REANALYZING CAROTID ARTERY STENOSIS TREATMENT CLINICAL TRIAL RESULTS FROM A BAYESIAN PERSPECTIVE
  Smolen HJ
Medical Decision Modeling Inc., Indianapolis, IN, USA
4:15PM-4:30PM MO3 APPLIED CONTRIBUTIONS TO THE EQ-5D HEALTH UTILITY INDEX
  Ghushchyan VH1, Sullivan PW2, Libby AM3
1University of Colorado Anschutz Medical Campus, School of Pharmacy, Aurora, CO, USA, 2Regis University School of Pharmacy, Denver, CO, USA, 3University of Colorado, Denver, Aurora, CO, USA
4:30PM-4:45PM MO4 EXAMINING ONTARIO'S UNIVERSAL INFLUENZA IMMUNIZATION PROGRAM WITH A NEW DYNAMIC INFLUENZA MODEL
  Thommes EW1, Bauch CT2, Meier G3, Chit A4
1GlaxoSmithKline Canada, Mississauga, ON, Canada, 2University of Guelph, Guelph, ON, Canada, 3GlaxoSmithKline Vaccines, King of Prussia, PA, USA, 4(formerly GlaxoSmithKline) Sanofi Pasteur Canada, Toronto, ON, Canada
 

PATIENT PROTECTION AND AFFORABLE CARE ACT & OTHER HEALTH CARE REFORM STUDIES

3:45PM-4:00PM PP1 THE IMPACT OF MASSACHUSETTS HEALTH CARE REFORM ON PATIENT OUTCOMES
  Sulham K, Armstrong S, Abraham J, Garfield S
GfK Bridgehead, Wayland, MA, USA
4:00PM-4:15PM PP2 THE IMPACT OF PATIENT PROTECTION AND AFFORDABLE CARE ACT REGULATIONS ON DRUG MANUFACTURERS' MEDICAID MARKET SEGMENT PROFITABILITY
  Chen T, Cost P, Gaitonde P
HERON Evidence Development LLC, Somerville, NJ, USA
4:15PM-4:30PM PP3 TRANSFORMATION OF SERVICES AND CARE PATHWAY REDESIGN IN THE NHS: FURTHER REFORMS IN HEALTH POLICY
  Mallinson M, King P
Access Partnership, London, UK
4:30PM-4:45PM PP4 WITHDRAWN
   
   
5:00PM-6:00PM
WORKSHOPS – SESSION I
5:00PM-6:00PM
W1: ECONOMETRIC METHODS FOR ASSESSING TREATMENT-EFFECT HETEROGENEITY
Discussion Leaders: Anirban Basu, MS, PhD, Associate Professor, Health Services, University of Washington, Seattle, WA, USA; David Vanness, PhD, Professor, Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA; Donald E. Stull, PhD, Director, Retrospective Data Analysis, RTI Health Solutions, Didsbury, Manchester, UK; David Thompson, PhD, Senior Vice President, Real World & Late Phase Research, Quintiles Outcome, Cambridge, MA, USA
5:00PM-6:00PM
W2: LEADING HORSES TO WATER: EXPERIMENTAL ANALYSIS OF CHOICE AND ADHERENCE IN DESIGNING PAY-FOR-PERFORMANCE AND OTHER FINANCIAL-INCENTIVES PROGRAMS
Discussion Leaders: F. Reed Johnson, PhD, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Florian Turk, PhD, Global Head, Health Economics & Outcomes Research, Critical Care Business Franchise, Novartis Pharma AG, Basel, Switzerland; Ateesha F. Mohamed, MA, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
5:00PM-6:00PM
W3: PRESENTING UNCERTAINTY (AND ITS CONSEQUENCES) IN COST EFFECTIVENESS TO BEST INFORM POLICY DECISIONS
Discussion Leaders: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Marta O. Soares, MSc, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Keith Abrams, MSc, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK; Sean D. Sullivan, PhD, Professor, Director & Associate Dean, Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
5:00PM-6:00PM
W4: CAPTURING PATIENT AND OBSERVER PERSPECTIVES FOR EVALUATING TREATMENTS FOR PEDIATRIC MENTAL HEALTH CONDITIONS - OPPORTUNITIES AND CHALLENGES
Discussion Leaders: Asha Hareendran, PhD, MA, Senior Research Scientist, United BioSource Corporation, London, United Kingdom Juliana Setyawan, Pharm, D, MS, Dr, Shire Development LLC, Wayne, PA, USA; Keith Saylor, PhD, Licensed Clinical Psychologist, NeuroScience Inc., Herndon, PA, USA; Elektra Papadopoulos, MD, MPH, Endpoints Reviewer, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
5:00PM-6:00PM
W5: ACCOUNTABLE CARE ORGANIZATION PHARMACEUTICAL READINESS: IS THE GLASS HALF-FULL, HALF-EMPTY, OR DO WE NEED A DIFFERENT GLASS?
Discussion Leaders: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA; Marv Feldman, MS, RPh, Managing Principal, Consulting Services Group, Premier Inc., Charlotte, NC, USA; Eleanor Perfetto, MS, PhD, Senior Director, Reimbursement & Regulatory Affairs, Federal Government Relations, Pfizer, Inc., Washington, DC, USA
5:00PM-6:00PM
W6: BEST PRACTICES AND PROMISING MODELS FOR PATIENT ENGAGEMENT IN PATIENT-CENTERED RESEARCH
Discussion Leaders: Kathleen W. Wyrwich, PhD, Senior Research Leader, United BioSource Corporation, Bethesda, MD, USA; Sue Sheridan, MIM, MBA, Director of Patient Engagement, Patient-Centered Outcomes Research Institute, Washington, DC, USA; Theresa Mullin, PhD, Director, Office of Planning and Informatics, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Steven I. Blum, MBA, Director, Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ, USA
5:00PM-6:00PM
W7: FROM OBSERVATION TO PERSONALIZED DECISION SUPPORT – HOW REAL WORLD EVIDENCE CONTRIBUTES TO THE ESTABLISHMENT OF E-SCREENING PROGRAMS
Discussion Leaders: Jacco A. Keja, PhD, Lecturer, IBMG, Erasmus University, Rotterdam, The Netherlands; Gabriel Chodick, PhD, Unit Director, Epidemiology & Database Research Unit, Maccabi Healthcare Services, Tel Aviv, Israel; Fabian Offer, PhD, Co-CEO, Medial Research Ltd, Ramot Hashavim, Israel
6:00PM-6:30PM
ISPOR ANNUAL BUSINESS MEETING
 

Call to order: Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR President
Executive Director's Report: Marilyn Dix Smith, RPh, PhD, ISPOR Executive Director
Treasurer's Report: Karen Rascati, RPh, PhD, ISPOR Treasurer
Audit Report: Kenneth KC Lee, MPhil, PhD, RPh
Value in Health Co-Editors-in-Chief Report: C. Daniel Mullins, PhD and Michael Drummond, PhD
Value in Health Regional Issues Co-Editor-in-Chief Report: Bong-min Yang, PhD, Federico Augustovski, MD, MSc, PhD,
and Dan Greenberg, PhD

ISPOR CONNECTIONS Editor-in-Chief Report: David Thompson, PhD
Member Open Discussion: ISPOR Members
New Business: Deborah Marshall, PhD, MHSA

6:00PM-7:45PM
6:15PM-7:15PM
ISPOR FORUMS – SESSION I
6:15PM-7:15PM CLINICIAN-REPORTED OUTCOMES (ClinROs): GOOD MEASUREMENT PRACTICES

Task Force members will define which outcome assessments should be considered ClinROs and make recommendations for the evaluation of ClinRO measures to support a labeling claim of treatment benefit. Presented by the ISPOR Clinician-Reported Outcomes (ClinROs) Good Measurement Practices Task Force

Moderator & Speaker: John H. Powers, III, MD, FACP, FIDSA, Senior Medical Scientist, Support to Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

Speakers: Laurie B. Burke, RPh, MPH, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, Washington, DC, USA; Donald Patrick, PhD, MSPH, Professor, Department of Health Services and Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

6:15PM-7:15PM PRINCIPLES OF GOOD PRACTICE FOR BUDGET IMPACT ANALYSIS

This forum will discuss updated guidelines for researchers and decision makers performing budget impact analyses or reviewing the results of such analyses in order to determine the affordability of new health care interventions. It will also address the role of health outcomes in assessing the budget impact. Presented by the ISPOR Budget Impact Analysis Good Practices II Task Force

Moderator: Sean Sullivan, PhD, Stergachis Family Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Speakers: Josephine Mauskopf, PhD, Vice President of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Senior Vice President, Research, United BioSource Corporation, Lexington, MA, USA, and Adjunct Professor of Medicine, Epidemiology & Biostatistics, McGill University, Montreal, PQ, Canada; Karen Lee, MA, Director, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada; Mark Minchin, MBA, Technical Adviser – PASLU, National Institute for Health and Clinical Excellence, Manchester, UK

6:15PM-7:15PM CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS)

The task force will present the 24-item CHEERS Statement that provides guidance on the minimum reporting requirements to optimize the reporting of health economic evaluations.  Examples and explanations for these recommendations will be included. Presented by the ISPOR Health Economic Evaluation Publication Guidelines Task Force

Moderator & Speaker: Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

Speakers: Andrew H. Briggs, MSc (York), MSc (Oxon), DPhil (Oxon), Associate Editor, Medical Decision Making, Co-Editor, Health Economics and William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Chris Carswell, MRPharmS, MSc, Editor, Pharmacoeconomics, Adis International, Auckland, New Zealand;
Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

6:15PM-7:15PM THE STUDENT FORUM: INCORPORATING PATIENT-CENTERED OUTCOMES WITHIN COMPARATIVE EFFECTIVENESS RESEARCH: IMPLICATIONS FOR CLINICAL PRACTICE, HEALTH CARE POLICY, AND STUDENT'S CAREER PATHS

How the integration of patient-centered outcomes in both clinical and comparative effectiveness research will affect patients, pharmacists, providers, and researchers in the coming years will be discussed.  Speakers will identify how young researchers can prepare themselves for future opportunities in patient-centered comparative effectiveness research. Presented by the ISPOR Student Council

Moderators: Zeba Khan, PhD, RPh, ISPOR Student Network Advisor and Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA; Emily Reese, MPH, ISPOR Student Network Chair and Graduate Research Assistant, University of Maryland, Baltimore, MD, USA

Speakers: C. Daniel Mullins, PhD, Professor, University of Maryland, Baltimore, MD, USA; Eleanor M. Perfetto, PhD, MS, Senior Director, Reimbursement and Regulatory Affairs, Pfizer, Washington, DC, USA; Danielle Lavallee, PhD, PharmD, Survey Center Senior Manager & Lead Researcher, University of Washington, Seattle, WA USA; Margaret Rothman, PhD, Senior Director, PRO Group, GSM&MA, Janssen Global Services, Washington, GA, USA

6:15PM-7:15PM HEALTH TECHNOLOGY ACCESS AMONG THE BRICS COUNTRIES: BRAZIL, RUSSIA, INDIA, CHINA, AND SOUTH AFRICA

The BRICS countries represent a dynamic arena for the positive implementation of pharmacoeconomics and outcomes research practices, with opportunities and challenges for health technology access for patients. Encompassing nearly 3 billion people with a combined GDP of US $14.0 trillion as of 2013, the opportunities for innovative technologies to improve health outcomes and quality of life are clear; however challenges like inequity of health care access, drug/device pricing, government formulary approval, procurement and supply chain logistics, and off-patent label competition all serve as barriers to patient access for new health technologies. This forum will outline the opportunities and challenges for health technology access among the BRICS countries, as well as highlight the importance of these emerging policy trends. Presented by the ISPOR Brazil, Russia, India, China, and South Africa Regional Chapters

Moderator & Speaker: Gabriela Tannus, MBA, MSc, President, ISPOR Brazil Chapter and Owner & Health Economics Director, Axia.Bio Consulting, Sao Paulo, Brazil

Speakers: Madhur Gupta, MD, DM, Technical Officer, Pharmaceuticals, World Health Organization Country Office for India, New Delhi, India; Wen Chen, PhD, President, ISPOR Shanghai Chapter, and Professor & Deputy Dean, School of Public Health, Fudan University, Shanghai, China; Vitaly V. Omelianovskiy, MD, PhD, President, ISPOR Russia HTA Chapter, Chairman of the Board, National Center for Technology Assessment in Health Care, and Deputy Director, Center for Monitoring and Clinical & Economic Evaluation, Moscow, Russia; Jacques Snyman, MBChB, MPharm Med, MD, President, ISPOR South Africa Chapter and Clinical Pharmacologist, Agility Global Health Solutions, Pretoria, South Africa

6:15PM-7:15PM HEALTH CARE DATA IN THE ARABIC-SPEAKING COUNTRIES: CHALLENGES IN COLLECTING, SHARING, AND APPLYING

Pharmacoeconomics and outcomes research require the use of primary data from Randomized Controlled Trials (RCTs) as well as other secondary and real world health care data. The lack of health care data creates a major barrier to the application of pharmacoeconomics and outcomes research in the Arabic-speaking countries. This forum will discuss the challenges in collecting, sharing, and applying data in pharmacoeconomic studies and outcomes research in these countries. Examples of the best strategies to overcome existing barriers to the availability and use of data in pharmacoeconomics and outcomes research will be provided. Speakers will shed light on the challenges and opportunities related to health care data availability and applications in Egypt, Jordan, Qatar, Saudi Arabia, and United Arab Emirates and will emphasize initiatives that need to be taken by the relevant authorities in these countries. Presented by the ISPOR Arabic Network

Moderator & Speaker: Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia

Speakers: Manal El-Hamamsy, BSPharm, PhD, Assistant Professor, Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Daoud Al-Badriyeh, PhD, President, ISPOR Qatar Chapter, Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar; Mohammed Al-Kelya, PhD, Head, Research Quality Management, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia; Ola G. Al Ahdab Albannay, PhD, PGD, RPh, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

6:45PM-7:45PM
Josephine A. Mauskopf, PhD, MHA
Josephine A. Mauskopf, PhD, MHA

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI-HS. She has worked in several areas of health economics including health benefits assessment for toxic substance or food safety regulations and economic evaluations of new health care interventions. Examples of her work in each of these areas include: estimation of the health benefits from banning several asbestos containing products; estimation of the QALYs lost from every foodborne illness and use of these estimates for cost utility analyses for determining the value of food safety regulations; development of methodological guidance for budget impact and population outcomes analyses for new health care interventions.  Dr. Mauskopf completed an 8-year term as Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia and is an author on many peer-reviewed publications.

Program - Tuesday, May 21, 2013
7:15AM-8:15AM
EDUCATIONAL SYMPOSIUM (Sponsored by Xcenda)
THE PROMISE OF PERSONALIZED MEDICINE – "GETTING IT RIGHT THE FIRST TIME"
8:30AM-2:15PM
8:30AM-10:30AM
WELCOME & SECOND PLENARY SESSION
WELCOME AND ISPOR SCIENTIFIC EXCELLENCE AWARDS PRESENTATIONS
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

INCOMING PRESIDENTIAL ADDRESS

William H. Crown, PhD
2012-2013 ISPOR President-elect and Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

2013 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARD
Announced by: Michael Drummond, PhD, University of York, Heslington, York, UK, and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Value in Health Co-Editors-in-Chief
Anna Teytelman, PhDAWARDEE: Anna Teytelman, PhD, Software Engineer, Google Inc., New York, NY, USA

For the paper, “Modeling the Effects of H1N1 Influenza Vaccine Distribution in the United States” Value Health 2012;15:158-66.

2013 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD
Presented by: Anirban Basu, PhD, Chair, ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research Committee, and Associate Professor, Department of Health Services, School of Public Health, and Adjunct Associate Professor, Economics and Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Seattle, WA, and Faculty Research Fellow, the National Bureau of Economic Research, Cambridge, MA, USA
Ping Wang, PhDAWARDEE: Ping Wang, PhD, Senior Biostatistician, Global Medical Affairs, Biogen Idec, Weston, MA, USA

For the paper, “Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial” Health Serv Outcomes Res Methodol 2012 June;12:182–99.

2013 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD
Presented by: Daniel C. Malone, PhD, RPh, Chair, ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Committee, and Professor, College of Pharmacy, & Associate Professor, College of Public Health, University of Arizona Tucson, AZ, USA
Marisa E. Domino, PhDAWARDEE: Marisa E. Domino, PhD, Professor, Health Policy and Management, the University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA

For the paper, “Does Managed Care Affect the Diffusion of Psychotropic Medications?” Health Econ. 2012 Apr; 21(4):428-43.

2013 ISPOR BERNIE J. O'BRIEN NEW INVESTIGATOR AWARD
Presented by: Shelby Reed, PhD, RPh, Chair, ISPOR Bernie J. O’Brien New Investigator Award Committee, Professor and Assistant Research Professor, Duke Clinical Research Institute, Durham, NC, USA
Jennifer Polinski, MPH, MSc, ScDAWARDEE: Jennifer Polinski, MPH, MSc, ScD, Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
 
During the first phases of the drug development process, researchers are focusing on a technology (drug) for treating a disease or disorder at a molecular or mechanism of action level. However, during the technology development process, when is the patient’s well-being actually taken into consideration - Phase II or Phase III or ever? During this session, whether the patient’s well-being ‘is’ or ‘is not’ being considered during the drug development process will be debated from the perspective of a pharmaceutical company, the FDA, and most importantly – the patient. This session will include a pharmaceutical company CMO, a patient advocate, and the FDA.
9:00 - 9:10AM Moderator:  Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services, University of Washington, Seattle, WA, USA
9:10 - 9:25AM

The Patient’s Well-being: The FDA’s Perspective on the Drug Development Process
Speaker: Laurie B. Burke, MPH, RPh, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

9:30 - 9:50AM The Patient’s Well-being: An Industry Perspective on the Drug Development Process
Speaker:  Freda C. Lewis-Hall, MD, FAPA, Executive Vice President & Chief Medical Officer, Pfizer, Inc., New York, NY, USA
9:50 - 10:10AM The Patient's Well-being: The Patient's Perspective on the Drug Development Process
Speaker: Gail Gibson Hunt, President & CEO, National Alliance for Caregiving, Bethesda, MD, USA
10:10 – 10:30AM DISCUSSION
10:30AM-11:00AM
11:00AM-12:00PM
ISSUE PANELS – SESSION II
11:00AM-12:00PM
CLINICAL OUTCOMES RESEARCH ISSUES
IP6: DO TRIAL DESIGN AND ENDPOINT SELECTION FOR TOMORROW'S CANCER DRUGS INCORPORATE PATIENT-CENTERED MEASURES AND MEET MULTIPLE STAKEHOLDER NEEDS?
Moderator: Alexander Warren Bastian, MBA, Principal Consultant, GfK Bridgehead, San Francisco, CA, USA
Panelists: Roy D. Baynes, MD, PhD, Senior Vice President, Oncology and Inflammation Therapeutics, Gilead Sciences Inc., Foster City, CA, USA; Christopher-Paul Milne, DVM, MPH, JD, Director of Research, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA; Ron L. Akehurst, BSc, Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, and Member, National Institute for Health and Clinical Excellence (NICE) Diagnostics Committee, Sheffield, UK
11:00AM-12:00PM
ECONOMIC OUTCOMES RESEARCH ISSUES
IP7: MODEL OR...ELSE? THE FUTURE OF ENHANCING THE GENERALISABILITY ACROSS LOCATIONS OF ECONOMIC EVALUATIONS
Moderator:

Andrew Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Department of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Panelists: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington,York, UK; Manuel Antonio Espinoza, MD, PhD, Lecturer, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile; Adrian Gheorghe, MSc, Doctoral Researcher, Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
11:00AM-12:00PM
IP8: CAN BAYESIAN ADAPTIVE CER TRIAL DESIGNS BRIDGE THE NEEDS OF PATIENTS, PAYERS, REGULATORS, AND MANUFACTURERS?
Moderator: Jack Ishak, PhD, Director and Senior Research Scientist, Biostatistics and Epidemiology, United BioSource Corporation, Bethesda, MD, USA
Panelists: Rachael Fleurence, PhD, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA; Charles E. Barr, MD, MPH, Medical Director, Head of Registries, Medical Affairs, Genentech, Inc., South San Francisco, CA, USA; Robert T. O'Neill, PhD, Director, Office of Biostatistics, Office of Translational Sciences, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA (Invited)
11:00AM-12:00PM
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP9: WHEN SHOULD OBSERVATIONAL STUDIES BE USED FOR DECISION-MAKING, OR WHEN WILL THE EMPEROR HAVE CLOTHES?
Moderator: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA
Panelists: Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Paul Wallace, MD, Senior Vice President and Director, Center for Comparative Effectiveness, The Lewin Group, Falls Church, VA, USA; Marcus Wilson, PharmD, President, HealthCore, Wilimington, DE, USA
11:00AM-12:00PM
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH: HIGH TOUCH OR HIGH TECH?
Moderator: Danielle Lavallee, PharmD, PhD, Lead Researcher & Senior Manager, Department of Surgery/Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA
Panelists: C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA; Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA; Rafael Alfonso, MD, PhD, Scientific Director, Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA
12:00PM-2:15PM
12:15PM-1:15PM
EDUCATIONAL SYMPOSIUM (Sponsored by RTI Health Solutions)
WILLINGNESS TO PAY, ABILITY TO PAY, AND MONEY-EQUIVALENT VALUE: MEASURING AND USING MONETIZED HEALTH BENEFITS
1:15PM-2:15PM
2:15PM-3:15PM
RESEARCH PODIUM PRESENTATIONS – SESSION III
 

DRUG USE & DISEASE MANAGEMENT STUDIES

2:15PM-2:30PM
DU1 TREATING ACUTE HEART FAILURE IN THE ELDERLY: A COMPARISON OF THREE INPATIENT TREATMENT ALTERNATIVES IN THE UNITED STATES
  Gradman AH1, Vekeman F2, Eldar-Lissai A3, Trahey A3, Lacomte P4, Ong SH4, Duh MS3
1Temple University School of Medicine, Pittsburgh, PA, USA, 2Groupe d'analyse, Montréal, QC, Canada, 3Analysis Group, Inc., Boston, MA, USA, 4Novartis Pharma AG, Basel, Switzerland
2:30PM-2:45PM
DU2 THE SHORT- AND LONG-TERM IMPACT OF CONSUMER-DRIVEN HIGH DEDUCTIBLE HEALTH PLANS ON MEDICATION USE
  Gibson TB1, Carls G1, Moore BJ1, Ehrlich ED1, Heithoff K2
1Truven Health Analytics, Ann Arbor, MI, USA, 2Merck & Co, Inc., Whitehouse Station, NJ, USA
2:45PM-3:00PM
DU3 COHORT ANALYSIS ASSESSING MEDICAL AND NON-MEDICAL COST ASSOCIATED WITH OBESITY IN THE WORKPLACE
  Abouzaid S1, Kleinman NL2, Andersen L3, Wang Z1, Powers A1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2The HCMS Group, Cheyenne, WY, USA, 3HCMS Group, Cheyenne, WY, USA
3:00PM-3:15PM
DU4 THE ASSOCIATION OF BURN INJURIES AND PSEUDOEPHEDRINE SALES
  Goodin AJ, Perin NR, Freeman PR, Talbert J, Wittmer D, Blumenschein K
University of Kentucky, Lexington, KY, USA
 

MEDICARE STUDIES

2:15PM-2:30PM
MD1 IMPACT OF MEDICARE PART D COVERAGE ON HEALTH OUTCOMES IN END-STAGE RENAL DISEASE
  Park H1, Rascati KL1, Lawson KA1, Barner J1, Richards K1, Malone DC2
1The University of Texas at Austin, Austin, TX, USA, 2University of Arizona, Tucson, AZ, USA
2:30PM-2:45PM
MD2 SKELETAL-RELATED EVENTS AND MORTALITY AMONG SEER-MEDICARE PATIENTS WITH METASTATIC PROSTATE CANCER: THE IMPLICATIONS OF MEASUREMENT APPROACH
  Onukwugha E1, Yong C1, Mullins CD1, Seal B2, Hussain A3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA
2:45PM-3:00PM
MD3 ASSOCIATION BETWEEN INHALED ANTICHOLINERGICS USE AND ALL-CAUSE MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH RESPIRATORY DISEASES
  Ajmera MR1, Pan X1, Findley P2, Rust G3, Sambamoorthi U4
1West Virginia University, Morgantown, WV, USA, 2Rutgers University, New Brunswick, NJ, USA, 3Morehouse School of Medicine, Atlanta, GA, USA, 4West Virginia University School of Pharmacy, Morgantown, WV, USA
3:00PM-3:15PM
MD4 GEOGRAPHIC VARIATION IN LOCAL MEDICARE COVERAGE FOR PART B BIOLOGICS
  Saret CJ, Cangelosi MJ, Chambers JD, Cohen JT, Neumann PJ
Tufts Medical Center, Boston, MA, USA
 

PRICING STUDIES

2:15PM-2:30PM
PR1 PAYER PERSPECTIVES ON DRUG PRICING, COVERAGE, AND REIMBURSEMENT IN OPHTHALMOLOGIC ORPHAN CONDITION IN THE UNITED STATES
  Gavaghan M1, Abraham J1, Pauer L2
1GfK Bridgehead, Wayland, MA, USA, 2Santen, Inc., Emeryville, CA, USA
2:30PM-2:45PM
PR2 SHORTCOMINGS OF EQ-5D IN A VALUE-BASED PRICING FRAMEWORK
  Tordrup D1, Mossman J2, Kanavos P3
1London School of Economics, London, UK, 2European Federation of Neurological Associations, Dublin, Ireland, 3London School of Economics and Political Science, London, UK
2:45PM-3:00PM
PR3 A CONTINGENT VALUATION SURVEY OF USER FINANCIAL INCENTIVES FOR HEALTH BEHAVIOUR CHANGE
  Meads DM, McCabe C, Camidge DC, Hill KM, House AO, Hulme CT
University of Leeds, Leeds, UK
3:00PM-3:15PM
PR4 THE IMPACT OF GENERIC DRUG POLICY ON DRUG PRICING
  Lee B1, Garay OU2, Goldhaber-Fiebert J3, Wilson LS1
1University of California, San Francisco, San Francisco, CA, USA, 2Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3Stanford University, Stanford, CA, USA
 

RISK MANAGEMENT STUDIES

2:15PM-2:30PM
RM1 PATIENT AND PHYSICIAN PREFERENCES IN THE UNITED STATES FOR BENEFITS AND RISKS OF ANTICOAGULANT USE IN ATRIAL FIBRILLATION – RESULTS FROM A CONJOINT-ANALYSIS STUDY
  Levitan B1, Yuan Z1, González JM2, Hauber AB2, Lees M3, Piccini JP4, Singer DE5, Nessel C6
1Janssen Research & Development, Titusville, NJ, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Duke University Medical Center, Durham, NC, USA, 5Harvard Medical School, Boston, MA, USA, 6Janssen Research & Development, Raritan, NJ, USA
2:30PM-2:45PM
RM2 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS AND RISK OF DEMENTIA IN HEART FAILURE
  Chitnis AS1, Johnson ML2, Aparasu RR2, Chen H2, Kunik ME3, Schulz PE4
1United BioSource Corporation, Lexington, MA, USA, 2University of Houston, Houston, TX, USA, 3Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Houston, TX, USA, 4The University of Texas Health Science Center at Houston, Houston, TX, USA
2:45PM-3:00PM
RM3 SULFONYLUREAS ARE ASSOCIATED WITH ELEVATED RISK OF HIP FRACTURES AMONG ELDERLY MEN AND WOMEN WITH TYPE-2 DIABETES
  Rajpathak SN1, Fu C1, Engel SS1, Brodovicz KG1, Lapane K2
1Merck & Co, North Wales, PA, USA, 2University of Massachussets, Worcester, MA, USA
3:00PM-3:15PM
RM4 EXTERNAL VALIDATION OF THE RISK-PREDICTION MODEL FOR HEPATOCELLULAR CARCINOMA [HCC] FROM THE REVEAL HCV STUDY
  Matsuda T1, Tonnu-Mihara I2, Yuan Y3, Hines P3, Saab S4, LItalien GJ5, McCombs J1
1University of Southern California, Los Angeles, CA, USA, 2VA Long Beach, Long Beach, CA, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 5Bristol Myers Squibb, Wallingford, CT, USA
 

SELECTION BIAS STUDIES

2:15PM-2:30PM
SB1 BURDEN OF SCHIZOPHRENIA ON SELECTED COMORBIDITIES COSTS
  Lafeuille MH1, Dean J2, Fastenau J3, Panish JM3, Olson WH3, Markowitz M3, Duh MS2, Lefebvre P1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Janssen Scientific Affairs, LLC, Titusville, NJ, USA
2:30PM-2:45PM
SB2 MEDICAL, DRUG, AND WORK-LOSS COSTS OF DIABETIC FOOT ULCERS
  Rice JB1, Desai U1, Cummings AK1, Birnbaum HG1, Skornicki M2, Parsons N2
1Analysis Group, Inc., Boston, MA, USA, 2Organogenesis Inc., Canton, MA, USA
2:45PM-3:00PM
SB3 THE PREVALENCE OF OPIOID-RELATED MAJOR POTENTIAL DRUG-DRUG INTERACTIONS AND THEIR IMPACT ON HEALTH CARE COSTS
  Summers K1, Pergolizzi J2, Ma L1, Foster D3, Overholser B3, Sowinski K3
1Endo Pharmaceuticals, Inc., Malvern, PA, USA, 2Johns Hopkins University, Naples, FL, USA, 3Purdue University College of Pharmacy, Indianapolis, IN, USA
3:00PM-3:15PM
SB4 TIME-SPECIFIC PROPENSITY SCORE ANALYSIS FOR OBSERVATIONAL STUDY: A CASE STUDY ESTIMATING THE EFFECTIVENESS OF THIAZOLIDINEDIONE USE
  Dilokthornsakul P1, Chaiyakunapruk N1, Lee T2
1Center of Pharmaceutical Outcomes Research, Naresuan University, Muang, Phitsanulok, Thailand, 2University of Illinois at Chicago, Chicago, IL, USA
   
3:15PM-3:45PM
3:45PM-7:45PM
3:45PM-4:45PM
WORKSHOPS – SESSION II
3:45PM-4:45PM
W8: ANIMATION OF DISCRETE EVENT SIMULATION MODELS: POWERFUL GOOD MODELING PRACTICE FOR VALIDATION, UNDERSTANDING, AND REPORTING
Discussion Leaders: Jorgen Moller, MSc, Vice President, Health Economic Modeling, United BioSource Corporation, Eslov, Sweden; Luis Hernandez, MSc, Research Associate, United BioSource Corporation, Lexington, MA, USA; Jay Patrick Bae, PhD, Principal Research Scientist, Global Health Outcomes, Eli Lilly & Company, Indianapolis, IN, USA
3:45PM-4:45PM
W9: ACCOUNTING FOR HETEROGENEITY, TEMPORAL UNCERTAINTY, AND IMPLEMENTATION IN UNCERTAINTY ASSESSMENT FOR HEALTH CARE DECISION-MAKING
Discussion Leaders: Susan Griffin, PhD, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Manuel Antonio Espinoza, MD, MSc, PhD, Scientific Advisor, Health Technology Assessment, Institute of Public Health, Santiago, Chile; Ronan Mahon, MSc, PhD Student, Centre for Health Economics, University of York, York, North Yorkshire, UK; Ties Hoomans, PhD, Assistant Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
3:45PM-4:45PM
W10: VALUE-BASED PRICING: GETTING IT RIGHT FOR PEOPLE WITH CANCER
Discussion Leaders: Jacque Anne Mallender, BA, MSc, Director, Matrix Knowledge, London, UK; Carole Anne Jones, MBA, Head of Pharmaceutical Advisory, Matrix Knowledge, London, UK; Alexis Wieroniey, BA (Hons), Senior Campaigns Officer, Prostate Cancer UK, London, UK
3:45PM-4:45PM
W11: MEASURING PATIENT REPORTED OUTCOMES IN RARE DISEASES
Discussion Leaders: Katy Benjamin, PhD, Director, Patient Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Bethesda, MD, USA; Andrew J. Lloyd, DPhil, Vice President, Patient Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK; Anne Pariser, MD, Associate Director for Rare Diseases, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Rahul Sasane, PhD, Global Market Access Strategy Lead – Hematology, Bayer Pharmaceuticals, Montville, NJ, USA
3:45PM-4:45PM
W12: DISCRETE-CHOICE EXPERIMENTS AND BEST-WORST SCALING: EMPIRICAL AND METHODOLOGICAL DIFFERENCES AND DOES CHOICE MATTER?
Discussion Leaders: F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada; Joris D. van Dijk, BSc, Student, Health Technology and Services Research, University of Twente, Enschede, The Netherlands; Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
3:45PM-4:45PM
W13: IDENTIFYING HIGH RISK OR HIGH VALUE PATIENT COHORTS: OVERVIEW OF METHODS AND APPLICATIONS OF PATIENT PHENOTYPING ANALYSES
Discussion Leaders: Howard Friedman, MS, PhD, Senior Partner, DataMed Solutions LLC, New York, NY, USA; Patrick Sullivan, PhD, MA, Associate Professor, School of Pharmacy, Regis University, Denver, CO, USA; Kristijan Kahler, PhD, RPh, Head, Outcomes Evidence & Analytics, Global Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
3:45PM-4:45PM
W14: USING ELECTRONIC MEDICAL RECORD (EMR) DATA FOR CONDUCTING RETROSPECTIVE STUDIES: OPPORTUNITIES AND PITFALLS
Discussion Leaders: Natalia Olchanski, MS, Project Director, Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Pei-Jung Lin, PhD, Assistant Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Kathy Lang, PhD, Senior Director, Boston Health Economics, Inc., Waltham, MA, USA; Aaron Winn, MPP, Research Associate II, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
5:00PM-6:00PM
WORKSHOPS – SESSION III
5:00PM-6:00PM
W15: INCORPORATING PATIENT LEVEL DATA IN A NETWORK META-ANALYSIS
Discussion Leaders: Jeroen P. Jansen, PhD, Vice President, Health Economics & Outcomes Research, MAPI Consultancy/Tufts University School of Medicine, Boston, MA, USA; Gorana Capkun-Niggli, PhD, Director, Global HE&OR, Novartis Pharma AG, Basel, Switzerland; Shannon Cope, MSc, Senior Research Manager, MAPI Consultancy, Boston, MA, USA
5:00PM-6:00PM
W16: SEQUENTIAL DECISION MODELING WITH MARKOV DECISION PROCESSES
Discussion Leaders: Jagpreet Chhatwal, PhD, Assistant Professor, Health Policy and Management, University of Pittsburgh, Pittsburgh, PA, USA; Oguzhan Alagoz, PhD, Associate Professor, Industrial Engineering, University of Wisconsin-Madison, Madison, WI, USA
5:00PM-6:00PM
W17: ONE SIZE DOES NOT FIT ALL: HOW TRADITIONAL PRICING AND REIMBURSEMENT POLICIES AFFECT ORPHAN DISEASE THERAPY
Discussion Leaders: Cyrus A. Chowdhury, MS, Chief Executive Officer, CBPartners, New York City, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow in Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK; Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA; Mónica Martín de Bustamante, AB, BE, Managing Director, Europe, Middle East, and Africa, CBPartners, Basel, Switzerland
5:00PM-6:00PM
W18: ONE OF THESE PATIENTS IS NOT LIKE THE OTHERS: DEVELOPMENT AND APPLICATION OF A TOOL FOR HEALTH CARE DECISION MAKERS TO ASSESS AND CONSIDER HETEROGENEITY IN COVERAGE DECISIONS
Discussion Leaders: Jennifer S. Graff, PharmD, Director, Comparative Effectiveness Research, National Pharmaceutical Council, Washington, DC, USA; Karen Van Nuys, PhD, Senior Research Economist, Precision Health Economics, Los Angeles, CA, USA; Michael X. West, PhD, Senior Payer Medical Science Liaison, GlaxoSmithKline, Research Triangle, NC, USA
5:00PM-6:00PM
W19: THE UTILITY OF MIXED-METHOD APPROACHES TO EVALUATE THE CONTENT VALIDITY OF PRO MEASURES
Discussion Leaders: William R. Lenderking, PhD, Senior Research Leader, United BioSource Corporation, Lexington, MA, USA; Cheryl Coon, PhD, Director, Psychometrics, RTI Health Solutions, Research Triangle Park, NC, USA; Sheri E. Fehnel, PhD, Vice President, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA; Laurie B. Burke, RPh, MPH, Director, Study Endpoints and Label Development, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
5:00PM-6:00PM
W20: PATIENTS MATTER — ENGAGING PATIENTS AS COLLABORATORS TO IMPROVE HEALTH CARE PLANNING, HEALTH SERVICE DELIVERY AND SELF-CARE
Discussion Leaders: Durhane Wong-Reiger, PhD, Chair, International Alliance of Patients' Outcomes, Toronto, ON, Canada; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada; Tracy Wasylak, MSc, CHE, Vice President, Strategic Clinical Networks & Clinical Care Pathways, Alberta Health Services, Calgary, AB, Canada; Nancy J. Marlett, PhD, Associate Professor, Community Rehabilitation and Disability Studies Community Health Sciences, University of Calgary, Calgary, AB, Canada
5:00PM-6:00PM
W21: WHAT'S IN A CLAIM? UNDERSTANDING THE SOURCES AND COMPONENTS OF ADMINISTRATIVE CLAIMS DATA
Discussion Leaders: Aylin Riedel, PhD, Vice President, OptumInsight, Eden Prairie, MN, USA; Henry Henk, PhD, Senior Fellow, OptumInsight, Eden Prairie, MN, USA; Donna L. Spencer, PhD, Senior Research Associate, School of Public Health, University of Minnesota, Minneapolis, MN, USA
6:00PM-7:45PM
6:15PM-7:15PM
ISPOR FORUMS – SESSION II
6:15PM-7:15PM MEET THE EDITORS OF VALUE IN HEALTH

This forum will provide attendees with the opportunity to meet with the editors of Value in Health.  Session topics include: What makes a great paper?  How will my paper be reviewed?  How can I volunteer to be a reviewer for Value in Health?  The editors will also be on hand to answer any other questions you may have about publishing in Value in HealthPresented by the Co-Editors-in-Chief of Value in Health.

Moderators/Speakers: Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research Department, University of Maryland, Baltimore, MD, USA

Speakers: Several Co-Editors of Value in Health will also participate in the discussion.

6:15PM-7:15PM USING MIXED MODES TO CAPTURE PATIENT-REPORTED OUTCOMES DATA IN CLINICAL TRIALS

Using different modes of data collection (e.g. paper and handheld device; IVR and Web) within clinical trials does occur.  Task Force recommendations regarding issues of measurement equivalence, migration, data quality and comparability, as well as analytical approaches for pooling of data, will be discussed. Presented by the ISPOR PRO Mixed Modes Good Research Practices Task Force

Moderator & Speaker: Sonya Eremenco, MA, Chair, ISPOR PRO Task Force: Good Research Practices for Mixed Modes to Collect PRO Data in Clinical Trials and ePRO Manager, United BioSource Corporation, Bethesda, MD, USA

Speakers: Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA; Jean Paty, PhD, Chief Scientist and Regulatory Advisor - Outcomes, ERT, Inc., Pittsburgh, PA, USA

6:15PM-7:15PM MARKET ACCESS CHALLENGES FOR IN VITRO DIAGNOSTIC: SIMILARITIES AND DIFFERENCES BETWEEN THE US AND EUROPEAN MARKETS

Global policies and expectations related to medical device and diagnostic technologies are evolving rapidly. This forum will provide detailed insights from the United States and Europe on similarities and differences in market access processes for in vitro diagnostics.  The discussion will focus on payer and health technology assessments (HTA) evidence requirement differences, evolving HTA methodologies, and current challenges for evidence generation.  Emerging challenges to achieving pricing and reimbursement given the rapidly changing technologies, such as next generation sequencing, and evolving coding systems will be highlighted.  Real-world examples of recent HTA for companion and high-value diagnostics in the United States and in Europe will be presented, as well as an overview of the molecular pathology coding and gap filling process in the United States, as it represents a “game changer” with regards to how laboratory developed tests versus FDA-approved tests are evaluated and paid-for. Presented by the ISPOR HTA Special Interest Group

Moderator: Susan Garfield, DrPH, Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA.

Speakers: Michael Longacre, BSc, Reimbursement Director, Corporate/ Shared Services, Becton Dickenson, Washington, DC, USA; Nick Poulios, PhD, Head, Medical Outcomes – Reimbursement & Economics, Roche Molecular Systems, Pleasanton, CA, USA; Eric Faulkner, MPH, Director, Global Market Access, Quintiles, Durham, NC, USA

6:15PM-7:15PM PRICING OF PHARMACEUTICALS IN EMERGING COUNTRIES OF THE CENTRAL AND EASTERN EUROPEAN REGION

Control of drug prices is one of the most important tools for pharmaceutical cost-containment policies. Policymakers pay attention to decisions and price control mechanisms in other countries. Therefore pricing policy decisions in one country may influence policy decisions and consequently health benefits of patients in other countries. This forum will discuss how the pharmaceutical price arsenal is applied in some emerging countries of Central and Eastern Europe. Preliminary findings of a Central and Eastern European policy survey on the implications of international pharmaceutical price referencing will also be presented. Presented by the ISPOR Central & Eastern Europe Network

Moderator & Speaker: Zoltán Kaló, MD, MSc, PhD, Director, Health Economics Research Centre, Eötvös Loránd University (ELTE), Syreon Research Institute, Budapest, Hungary

Speakers: Vitaly Omelianovskiy, MD, PhD, President, ISPOR HTA Russia Chapter and Professor & Chairman of the Board, National Center for Technology Assessment in Health Care; Deputy Director, Center for Monitoring and Clinical & Economic Evaluation Organization, National Center for Health Technology Assessment, Moscow, Russia; Joanna Lis, MSc, PhD, President, ISPOR Poland Chapter; Adjunct Professor, Pharmacoeconomics Department, Medical University of Warsaw; Director, Public Affairs and Market Access, Sanofi Poland, Warsaw, Poland; Vlad Zah, PhD (c) and Health Economics Consultant, Belgrade, Serbia; Olga Zaliska, PhD, Dr.Sci (Pharm), President, ISPOR Ukraine Chapter and Professor, Department of Organization & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

6:15PM-7:15PM IMPROVING HEALTH CARE EQUALITY IN RUSSIA

(Presented in Russian with slides in English)
This forum will review recent initiatives of the ISPOR Russia Chapter during its 15 years “on the road”, protecting and improving equality in health care in Russia. Representatives from the ISPOR Russia Chapter, the HTA Institute, and the Eurasian Alliance of Pharmacoeconomics Societies will describe their scientific, educational, and policy related activities during the last 15 years. Presented by the ISPOR Russia Regional Chapter.

Moderator: Pavel A. Vorobiev, MD, PhD, MS,  President, ISPOR Russia Regional Chapter, Professor & Head, Department of Hematology and Geriatrics and Faculty, Postgraduate Medical Education, First Sechenov Moscow State Medical University, Moscow, Russia

Speakers: Liubov Krasnova, MD, PhD, Senior Researcher, Department of Hematology and Geriatrics, First Sechenov Moscow Medical University, Moscow, Russia; Lyudmila Bezmelnitsina, MD, Faculty, Postgraduate Medical Education, First Sechenov Moscow Medical University, Moscow, Russia; Malwina Holownia, MPharm, Head, Department of Economics, First Sechenov Moscow Medical University, Moscow, Russia

6:15PM-7:15PM ECONOMIC ASSESSMENT IN AFRICA: DEVELOPMENT OF HEALTH ECONOMIC EVALUATION REPORTING

Health technology assessments that encompass economic evaluations are essential to the efficiency and sustainability of every health care system. With the differences in health costs and clinical care practice between countries, investments in health economics and development of economic evaluation guidelines help to make better decisions. Improving the quality and uniformity of economic evaluations reporting increases its value to decision makers. This forum will provide an overview of the development of health economic evaluation reporting in African countries. The presentation will provide a platform to discuss commonalities as well as differences and specific issues related to economic evaluation and its role in the cost-effectiveness of health care delivery in Africa. A country-specific analysis will be provided from speakers representing: Egypt, Ghana, Nigeria, and South Africa. Presented by the ISPOR Egypt, Ghana, Nigeria and South Africa Regional Chapters

Moderator & Speaker: Jacques Snyman, MBChB, MPharm Med, MD, President, ISPOR South Africa Chapter and Clinical Pharmacologist, Agility Global Health Solutions, Pretoria, South Africa

Speakers: Manal El-Hamamsy, BSPharm, PhD, Assistant Professor, Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Peter Agyei-Baffour, PhD, Health Economics Lecturer, Community Health Department, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Anthony Waka Udezi, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

6:15PM-7:15PM The Role of HTA in the Brazilian Pricing & Reimbursement Process: Lessons Learned and Challenges Ahead

Pricing and reimbursement are real challenges for anyone who wants to achieve success in the Brazilian market, currently one of the largest markets in the word. This forum will discuss how HTA, a mandatory step in the pricing and reimbursement process, came about in the Brazilian market, changed the local landscape, and the resulting issues that arose. Future trends will also be discussed from the local perspective. Presented by the ISPOR Brazil Regional Chapter.

Moderator: Stephen Doral Stefani, MD, Medical Auditor, Head of Oncology Unit, UNIMED, Porto Alegre, Brazil

Speakers: Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Consulting, São Paulo, Brazil; Marcelo Fonseca, MD, MSc,Professor, Health Technology Assessment and Clinical Research, Federal University of São Paulo (UNIFESP), Director, Axia.Bio, Pediatrician, Private Practice, and Assistant Physician, Pediatric Intensive Care Unit, University of São Paulo Faculty of Medicine Clinics Hospital, São Paulo, Brazil; Clarice Petramale, MD, Director, Unified Health System (SUS – Sistema Único da Saúde), Brazilian Ministry of Health, Brasilia, Brazil; Flávia Elias, PhD (Health Science), Head of the HTA Unit - DECIT/SCTIE, Brazilian Ministry of health, Brasilia, Brazil

6:45PM-7:45PM
8:00PM-11:30PM
ISPOR SOCIAL EVENT - Featuring the ISPOR Monte Carlos

Dinner, Live Music & Dancing at the House of Blues, located in the historic French Quarter!

Richard C. Larson, PhD
Richard C. Larson, PhD

Dr. Larson is MIT Mitsui Professor in the Engineering Systems Division and a member of the National Academy of Engineering (NAE).  He is founding director of MIT’s Center for Engineering System Fundamentals.  He has focused on operations research as applied to services industries, primarily in the fields of health care, disaster preparedness, technology-enabled education, urban service systems, queueing, logistics and workforce planning.  He is Past-President of INFORMS, Institute for Operations Research and the Management Sciences. He is an INFORMS Founding Fellow, and a recipient of the INFORMS President’s Award, Lanchester Prize and Kimball Medal.  He has served on a variety of panels and committees for the NAE and the IOM (Institute of Medicine).

His current MIT research includes disaster preparedness, especially pandemic influenza; K-12 STEM education; home energy management; and Ph.D.-level workforce planning for the NIH.

Marisa E. Domino, PhDMarisa Elena Domino, Ph.D

Marisa Elena Domino, Ph.D., is a Professor in the Department of Health Policy and Management in the Gillings School for Global Public Health at the University of North Carolina at Chapel Hill. She received her Ph.D. in Health Economics from the Johns Hopkins University and completed a Postdoctoral Fellowship in the economics of mental health at Harvard Medical School’s Department of Health Care Policy. Dr. Domino’s research interests include the economics of mental health, agency relationships among physicians, patients and insurers, the diffusion of new technologies, and the public provision of health care and health insurance to low income populations. Dr. Domino completed a K01 Career Development Award from the National Institute of Mental Health to analyze factors that affect the diffusion of psychotropic medications in a variety of populations. She has worked on a variety of projects on insurance design, behavioral health, and chronic illness including papers on the use medical homes in specialty care populations, behavioral health carve-outs, and assertive community treatment.

Anna Teytelman, PhDAnna Teytelman

Anna Teytelman received her PhD from MIT's Operation Research Center in June of 2012. Her research focuses on mitigating pandemic influenza spread, in particular using evidence from previous outbreaks to inform dynamic decision-making during future pandemic events. Research topics include dynamic vaccine allocation algorithms and techniques for evaluating non-pharmaceutical intervention effectiveness. She is currently working at Google in New York as a software engineer.

Ping Wang, PhDPing Wang, PhD

Ping Wang, PhD, a senior biostatistician, joined Global Medical Affairs team at Biogen Idec in February 2013. Before that, she was a project statistician at Eli Lilly and Company, supporting Global Health Outcomes. She is interested in developing and applying statistical methods in the area of health economics and outcomes research, such as joint modeling of longitudinal and survival data. She has worked on patient-reported outcome (PRO)-related projects across multiple therapeutic areas, including oncology, autoimmune, and diabetes. In addition, she worked on observational studies using large health care claims data to provide information on cost, resource utilization, adherence, etc. Ping obtained her PhD degree in statistics at the University of Wisconsin-Madison in 2009. During her graduate studies, her research was focused on the development and application of statistical methods for high-throughput genomics studies, such as microarrays and expression quantitative trait loci (eQTL) mapping studies.

Jennifer Polinski, MPH, MSc, ScDJennifer M. Polinski, ScD, MPH, MS

Jennifer M. Polinski, ScD, MPH, MS (MPH, Health Education, Emory University; MS and ScD, Epidemiology, Harvard School of Public Health) is an epidemiologist and health services researcher in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston, MA.  She holds faculty appointments at Harvard Medical School and Harvard School of Public Health, where she teaches a course in epidemiologic methods applied to health services research.  Dr. Polinski’s research interests focus on the management and treatment of chronic disease, patient and physician education, and the impact of health interventions and health policy changes on elderly populations.  She has a special interest in government-funded health care programs.  Her recent work examined changes in Medicare beneficiaries’ drug utilization and health outcomes following the inception of the Medicare Part D program.  Current projects include identifying predictors of type 2 diabetes treatment progression, developing tools to improve primary medication adherence, and studying methods for causal inference in comparative effectiveness studies. 

Program - Wednesday, May 22, 2013
8:30AM-2:45PM
8:30AM-9:30AM
ISSUE PANELS – SESSION III
8:30AM-9:30AM
ECONOMIC OUTCOMES RESEARCH ISSUES
IP11: WHOSE PERSPECTIVE SHOULD DETERMINE THE VALUE OF PERSONALIZED MEDICINE – THE PATIENT, THE PHYSICIAN OR SOCIETY?
Moderator: Maarten J IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Panelists: F Reed Johnson, PhD, Principal economist, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada; Kathryn Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA
8:30AM-9:30AM
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP12: SETTING PRIORITIES IN RESEARCH: DOES VALUE OF INFORMATION ANALYSIS HAVE A ROLE?
Moderator: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Panelists: Susan Griffin, PhD, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA; Rachael Fleurence, PhD, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA
8:30AM-9:30AM
IP13: PRESCRIPTION DRUG MONITORING PROGRAMS: ARE WE WALKING THE TIGHTROPE BETWEEN CONTROLLED SUBSTANCE ACCESS AND ABUSE?
Moderator: Patricia R. Freeman, PhD, Clinical Associate Professor, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA
Panelists: Cheryl Anderson, BSPharm, Director, South Carolina Prescription Monitoring Program and President, Alliance of States with Prescription Monitoring Programs, Bureau of Drug Control, South Carolina Department of Health and Environmental Control, Columbia, SC, USA; Bob Twillman, PhD, FAPM, Director of Policy and Advocacy, American Academy of Pain Management, Lenexa, KS, USA; Jeffery Talbert, PhD, Associate Professor & Director, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA
8:30AM-9:30AM
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH
IP14: WHAT ARE THE EMERGING STANDARDS, BARRIERS, AND SOLUTIONS FOR PATIENT-REPORTED OUTCOMES IN PERFORMANCE EVALUATION AND QUALITY IMPROVEMENT?
Moderator: Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC, USA
Panelists: Phyllis Torda, PhD, Vice President of Strategic and Quality Solutions Group, National Committee for Quality Assurance (NCQA), Washington, DC, USA; Collette Pitzen, RN, BSN, CPHQ, Clinical Measure Development Manager, MN Community Measurement, Minneapolis, MN, USA; Karen Pace, PhD, MSN, Senior Director, Performance Measures, National Quality Forum, Washington, DC, USA
8:30AM-9:30AM
IP15: CAN WE USE SOCIAL MEDIA TO SUPPORT CONTENT VALIDITY OF PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS IN MEDICAL PRODUCT DEVELOPMENT?
Moderator: Margaret Rothman, PhD, Senior Director, Patient Reported Outcomes, Janssen, Washington, GA, USA
Panelists: Ari Gnanaskathy, MSc MBA, Head, Patient Reported Outcomes, Patient Reported Outcomes, Novartis Pharmaceutical Corp, East Hanover, NJ, USA; Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA; Elektra Papadopoulos, MD, MPH, Endpoints Reviewer, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
9:30AM-9:45AM
9:45AM-11:00AM
WELCOME & THIRD PLENARY SESSION
WELCOME
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

 

ISPOR, as part of the AMCP/ISPOR/NPC Comparative Effectiveness Collaborative Initiative, has developed questionnaires to help health care decision makers assess and effectively use available data, with the goal of improving evidence-based health care decision making and ultimately improving patient health. The questionnaires focus on ‘relevance’ and ‘credibility’ when assessing the evidence from prospective and retrospective observational studies, as well as modeling and indirect treatment comparison evidence synthesis studies. These educational questionnaires help users in reviewing evidence and provide information and assistance in the review and effective use of the information.  To enhance the functionality and accessibility, ISPOR has developed an interactive version for these four types of studies.  During this session, the elements of the interactive questionnaires, as well as their use by health care decision-makers for better patient care, will be presented.

9:45 - 9:55AM Moderator: Joseph C. Cappelleri, PhD, MS, MPH, Senior Director, Pfizer Inc., Groton, CT, USA
9:55 - 10:05AM Assessing Prospective Observational Studies for Health Care Decisions
Speaker: Marc Berger, MD, VP Real World Data and Analytics, Pfizer, Inc., New York, NY, USA
10:05 - 10:15AM Assessing Retrospective Observational Studies for Health Care Decisions
Speaker: Bradley Martin, PhD, Professor and Division Chair, University of Arkansas for Medical Sciences, College of Pharmacy, Department of Pharmacy Practice, Little Rock, AR, USA
10:15 - 10:25AM Assessing Indirect Treatment Studies for Health Care Decisions
Speaker:  Jeroen Jansen, PhD, Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA
10:25 - 10:35AM Assessing Modeling Studies for Health Care Decisions
Speaker:  J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ, Canada
10:35 - 10:45AM A User's Perspective on Assessing Observational, Indirect Treatment, and Modeling Studies
AMCP Speaker: Karen Worley, PhD, Research Leader, Comprehensive Health Insights, Humana, Inc., Cincinnati, OH, USA
AMCP Speaker: Sherry Andes, PharmD, Drug Intelligence Supervisor, Catamaran, Lisle, IL, USA
10:45 - 11:00AM DISCUSSION
11:00AM-11:30AM
ISPOR 18th ANNUAL INTERNATIONAL MEETING RESEARCH PRESENTATION & SERVICE AWARDS
 
ISPOR SERVICE AND DISTINGUISHED SERVICE AWARDS

Presented by: Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

ISPOR STUDENT AWARDS
Presented by: Zeba M. Khan, PhD, RPh, ISPOR Student Network Advisor & VP, Pricing & Market Access, Celgene Corporation, Summit, NJ, USA
ISPOR BEST PODIUM PRESENTATIONS
Presented by: Onur Baser, PhD, MS, MA, President, STATinMED and Adjunct Professor of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
ISPOR BEST POSTER PRESENTATIONS
Presented by: Jeff J. Guo, PhD, Professor, Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati Medical Center College of Pharmacy, Cincinnati, OH, USA
PhRMA FOUNDATION 2013 AWARDS IN HEALTH OUTCOMES
Presented by: Jean Paul Gagnon, PhD, Chairman, PhRMA Foundation Health Outcomes and CER Advisory Committees, Washington, DC, USA
11:30AM-1:45PM
11:45AM-12:45PM
EDUCATIONAL SYMPOSIUM (Sponsored by CPRD)
FAST ACCESS TO BIG NATIONAL HEALTH CARE DATA SETS
12:45PM-1:45PM
1:45PM-2:45PM
WORKSHOPS – SESSION IV
1:45PM-2:45PM
W22: MODELS IN THE CLOUD - IMPROVING THE APPLICATION OF ECONOMIC MODELS WITH DYNAMIC DATA ANALYTICS AND A WEB-BASED GRAPHICAL USER INTERFACE
Discussion Leaders: Mei Xue, MBA, Senior Analyst, Pharmerit International, Bethesda, MD, USA; Cindy (Xin) Gao, PhD, Director, Health Economics, Pharmerit North America, LLC, Bethesda, MD, USA; Gijs Hubben, PhD, CEO, BaseCase Software, Berlin, Germany; Prabashni Reddy, PharmD, Director, Center for Drug Policy Partners Healthcare, Needham, MA, USA
1:45PM-2:45PM
W23: IMPROVING MEDICARE STAR RATINGS: EVIDENCE IN SUPPORT OF THE USE OF PATIENT MEDICATION ADHERENCE PACKAGING AS AN EFFECTIVE AND MEASURABLE ADHERENCE INTERVENTION
Discussion Leaders: Carolyn Harley, PhD, MPA, Director, Market Access, Value Strategy and Health Policy, OptumInsight Life Sciences, Palo Alto, CA, USA Elizabeth Whalley Buono, RN, MBA, JD, Vice President, Global Quality, Regulatory & External Affairs, MWV Healthcare, Richmond, VA, USA; Barbara K. Zedler, MD, Chief Medical Officer, Venebio Group, LLC, Richmond, VA, USA; Sandy Eyerly, Director, Managed Markets, MWV Healthcare, Richmond, VA, USA
1:45PM-2:45PM
W24: NOVEL APPROACHES IN EARLY PLANNING FOR RELEVANT EVIDENCE GENERATION TO SUPPORT HEALTH CARE DECISION MAKING
Discussion Leaders: L. Clark Paramore, MSPH, Senior Research Scientist, Health Economics, United BioSource Corporation, Lexington, MA, USA; Rob Thwaites, MA, Vice President, Health Economics, United BioSource Corporation, London, UK; Floortje E. van Nooten, MSc, Associate Director, HEOR, Astellas, Leiden, The Netherlands; Jan E. Hansen, PhD, DrPH, Vice President, Global Health Outcomes, Allergan, Irvine, CA, USA
1:45PM-2:45PM
W25: CHOICE DEFINES VALUE: NEW APPROACHES TO EVALUATING MULTIPLE TREATMENT ATTRIBUTES AND HEALTH OUTCOMES
Discussion Leaders: Benjamin M. Craig, PhD, Assistant Faculty Member, Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL, USA; Juan Marcos González, PhD, Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Axel Mühlbacher, PhD, MBA, Professor of Health Economics and Health Care Management, IGM Institute Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany
1:45PM-2:45PM
W26: EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
Discussion Leaders: Daniel M. Huse, MA, Vice President, Truven Health Analytics, Cambridge, MA, USA; Patricia A. Russo, PhD, MSW, RN, Vice President, Integrated Analytic Services, Quintiles, Washington, DC, USA; Joseph Vasey, PhD, Director, Epidemiology, Integrated Analytic Services, Quintiles, Bellefonte, PA, USA; Emily Durden, PhD, Research Leader, Outcomes Research, Truven Health, Austin, TX, USA
2:45PM-3:00PM
3:00PM-4:00PM
WORKSHOPS – SESSION V
3:00PM-4:00PM
W27: EVALUATIONS OF TREATMENT PATHWAYS IN ONCOLOGY: CLINICAL AND ECONOMIC CONSIDERATIONS AND MODELING APPROACHES
Discussion Leaders: Sonja Sorensen, MPH, Senior Research Scientist, United BioSource Corporation, Bethesda, MD, USA; Feng Pan, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA; Jianming He, MS, MA, Associate Director, Janssen Global Services LLC, Raritan, NJ, USA; Kevin Knopf, MD, MPH, Medical Oncologist, California Pacific Medical Center, San Francisco, CA, USA
3:00PM-4:00PM
W28: ADAPTING AMCP FORMAT-BASED DOSSIERS: EVIDENCE GUIDELINES FOR SPECIALTY PHARMACEUTICALS, COMPANION DIAGNOSTICS, AND COMPARATIVE EFFECTIVENESS RESEARCH
Discussion Leaders: Jeff Lee, PharmD, National Director, Regional Scientific Services, Allergan. Inc., Franklin, TN, USA Bryan R. Luce, PhD, MBA, Chief Science Officer, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Pete Penna, PharmD, President, Formulary Resources, LLC, Mercer Island, WA, USA; David L. Veenstra, PhD, PharmD, Professor, Department of Pharmacy, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
3:00PM-4:00PM
W29: DON'T FORGET ABOUT THE PATIENT! LISTENING TO PATIENTS AND INVOLVING THEM IN RESEARCH
Discussion Leaders: John Doyle, PhD, Senior Vice President, Drug Development Consulting, Quintiles, Inc., Hawthorne, NY, USA; Veronica Todaro, MPH, Director of National Programs, Parkinson's Disease Foundation (PDF), New York, NY, USA; John Reites, BS, Director, Operations, Digital Patient Unit, Quintiles, Inc., Durham, NC, USA
3:00PM-4:00PM
W30: DEPLOYING EPRO INSTRUMENTS IN CLINICAL TRIALS: CHALLENGES AND SOLUTIONS
Discussion Leaders: Tara Symonds, PhD, Senior Director, Outcomes Research, Pfizer, Inc., Kent, UK; Valdo Arnera, MD, General Manager, Europe, PHT Corporation, Geneva, Switzerland, Switzerland; J. Jason Lundy, PhD, Assistant Director, Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA; Cindy Howry, MS, Principal, ePRO Solutions, Bracket, Austin, TX, USA
3:00PM-4:00PM
W31: THE USE OF PATIENT-CENTERED HEALTH CARE INFORMATION FROM SOCIAL NETWORKING SOURCES IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
Discussion Leaders: Luke Boulanger, MA, MBA, Senior Research Scientist & Senior Director, Health Economics, United BioSource Corporation, Lexington, MA, USA; Doug McClure, MIM, Chief Technology Officer, Healthrageous, Boston, MA, USA; L. Clark Paramore, MSPH, Senior Research Scientist, Health Economics, United BioSource Corporation, Lexington, MA, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2014 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.